Disitamab Vedotin Plus Toripalimab Projected Cost-Effective for HER2-Overexpressing Advanced Urothelial Carcinoma
A partitioned survival model indicates that first-line disitamab vedotin plus toripalimab is cost-effective compared to chemotherapy alone for HER2-overexpressing advanced ...

